4 results about "Activated Lymphocyte" patented technology

The present application provides chimeric anti-CD27 antibody molecules and encoding nucleic acids and expression vectors thereof. The anti-CD27 antibody molecules of the present application can specifically bind to CD27 and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The present application provides a chimeric anti-CD27 antibody molecule composition and its application. The anti-CD27 antibody molecule of the present application can specifically bind to CD27 and has the effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The invention provides an in-vitro or ex-vivo method of expanding lymphocytes and a population of expanded tumor infiltrating lymphocytes (TILs) for use in a method for treating cancer comprising providing a population of lymphocytes, wherein the lymphocytes are from a biological sample; culturing the lymphocytes in a growth medium; expanding the lymphocytes in an expansion medium comprising nutrients and differentiation factors and / or cytokines, wherein the differentiations factors and / or cytokines comprise or consist of interleukin-2, interleukin-7, interleukin-15, and interleukin-21; obtaining expanded lymphocytes.

The present application relates to the field of cell therapy, in particular to a regulatory T cell targeting IL12RB1 and use thereof. The regulatory T cell provided by the present application comprises a P40 subunit or a mutant thereof. The present application uses a natural protein sequence, which can avoid the immunogenicity risk of antigens caused by scFv; and enables Treg cells to home to inflammatory sites and inhibit activated lymphocytes.